2. Search Result
Search Result
Isoforms Recommended: Metallo-β-lactamase
Results for "

NDM-1

" in MedChemExpress (MCE) Product Catalog:

35

Inhibitors & Agonists

4

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-150758
    NDM-1 inhibitor-3

    		Beta-lactamase Bacterial Infection
    NDM-1 inhibitor-3 (Compound 89) is a New Delhi Metallo-β-lactamase-1 (NDM-1) inhibitor with a Ki of 4 μM [1].
    NDM-1 inhibitor-3
  • HY-148493
    MK-3402

    		Bacterial Infection
    MK-3402 (Compound303) is a metallo-beta-lactamase inhibitor, with IC50 values of 0.53, 0.25 and 0.169 nM against IMP-1, NDM-1, and VIM-1, respectively. MK-3402 can be used in bacterial research and shows a synergistic effect when used in combination with beta-lactam antibiotics [1].
    MK-3402
  • HY-118013
    NDM-1 inhibitor-2

    		Others Infection
    NDM-1 inhibitor-2 is an inhibitor of New Delhi metallo-β-lactamase-1 (NDM-1) and has the ability to inhibit NDM-1 activity. NDM-1 inhibitor-2 exhibits a good inhibitory effect on drug-resistant bacterial strains that overexpress NDM-1. When NDM-1 inhibitor-2 is used in combination with the carbapenem antibiotic meropenem, a favorable synergistic effect can be produced [1].
    NDM-1 inhibitor-2
  • HY-163190
    NDM-1 inhibitor-4

    		Bacterial Infection
    NDM-1 inhibitor-4 (compound 27) is a NDM-1 inhibitor with Ki of 1.7 μM. NDM-1 inhibitor-4 has antimicrobial effect [1].
    NDM-1 inhibitor-4
  • HY-163191
    NDM-1 inhibitor-5

    		Beta-lactamase Bacterial Infection
    NDM-1 inhibitor-5 (compound 57) is a potent NDM-1 inhibitor, with a Ki of 2.5 μM. NDM-1 inhibitor-5 also shows antibacterial synergistic activity with meropenem (HY-13678) [1].
    NDM-1 inhibitor-5
  • HY-155202
    YJ196

    		Others Others
    YJ196 (Compound 59) is a New Delhi Metallo-β-lactamase-1 (NDM-1) inhibitor [1].
    YJ196
  • HY-155283
    Zndm19

    		Beta-lactamase Bacterial Infection
    Zndm19 is a New Delhi Metallo-β-lactamase-1 (NDM-1) inhibitor. Zndm19 can be used for the research of drug-resistant bacterial infections [1].
    Zndm19
  • HY-150260
    SA09-Cu

    		Bacterial Infection
    SA09-Cu is a noncompetitive and potent NDM-1 inhibitor with an IC50 of 9.6 nM. SA09-Cu can convert NDM-1 into an inactive state by oxidizing the Zn(II)-thiolate site of the enzyme and avoids to be reduced by intracellular thiols of bacteria. SA09-Cu exhibits excellent inhibition against a series of clinical NDM-1-producing carbapenem-resistant Enterobacteriaceae (CRE) in restoring the Meropenem (HY-13678) effect, and slows down the development of carbapenem resistance [1].
    SA09-Cu
  • HY-152105
    Metallo-β-lactamase-IN-9

    		Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-9 (Compound 23) is a pan metallo-beta-lactamase (MBL) inhibitor with IC50s of 35, 269 and 369 nM against NDM-1, VIM-1 and IMP-1, respectively [1].
    Metallo-β-lactamase-IN-9
  • HY-149929
    EBL-3183

    		Beta-lactamase Bacterial Infection
    EBL-3183, an indole-2-carboxylate, is a potent metallo-β-lactamase (MBL) inhibitor. EBL-3183 is reversibly binding, non-covalent, competitive NDM-1 inhibitor with a pIC50 of 7.7 [1].
    EBL-3183
  • HY-12826
    IMB-XH1

    		Beta-lactamase Bcl-2 Family Bacterial Cancer
    IMB-XH1 is an inhibitor of myeloid cell factor 1 (Mcl-1) [1]. IMB-XH1 is a non-competitive Delhi metallo-β-lactamase (NDM-1) inhibitor. The IC50s of IMB-XH1 against metallo-β-lactamases NDM-1, IMP-4, ImiS and L1 are 0.4637 μM, 3.980 μM, 0.2287 μM and 1.158 μM, respectively .
    IMB-XH1
  • HY-121765
    Dacisteine

    N,S-Diacetyl-L-cysteine

    		 Endogenous Metabolite Metabolic Disease
    Dacisteine (N,S-Diacetyl-L-cysteine) is a cysteine derivative and displays a less New Delhi metallo-beta-lactamase-1 (NDM-1) inhibitor with an IC50 value of 1000 μM [1]. Dacisteine can be used for the treatment of cardiovascular and cerebrovascular diseases caused by platelet aggregation .
    Dacisteine
  • HY-155504
    Metallo-β-lactamase-IN-11

    		Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-11 (compound 5f) is a Metallo-β-lactamases (MBLs) inhibitor, potent against bacterial metallophyllactamase CphA (IC50=45 µM). Metallo-β-lactamase-IN-11 (10 µM) inhibits NDM-1 by 49% and AIM-1 by 61%. Metallo-β-lactamase-IN-11 can be used in the research of inhibiting antibiotic resistance [1].
    Metallo-β-lactamase-IN-11
  • HY-168500
    Metallo-β-lactamase-IN-16

    		Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-16 (compound 18) is a sulfone containing metallo-β-lactamase inhibitor with an anti-bacterial activity. Metallo-β-lactamase-IN-16 inhibits NDM-1 (New Dehli metallo-β-lactamase-1), IMP-1 (imipenemase-1), VIM-1 (Verona integron-encoded metallo-β-lactamase), and VIM-2 with IC50 values of 0.16 nM, 0.23 nM, 0.31 nM and 1.0 nM, respectively [1].
    Metallo-β-lactamase-IN-16
  • HY-144229
    trans-Cephalosporin

    		Others Inflammation/Immunology
    Trans substituted cephalosporin is an effective NDM-1 inhibitor，with an IC50 value of 0.13 μM.
    trans-Cephalosporin
  • HY-129200
    Aspergillomarasmine A

    		Others Others
    Aspergillomarasmine A is a natural aminopolycarboxylic acid with potent inhibitory activity against class B metallo-β-lactamases (MBLs). Aspergillomarasmine A inactivates MBLs by removing a catalytic Zn2+ cofactor. Aspergillomarasmine A acts as a selective Zn2+ scavenger, promoting the dissociation of the metal cofactor, thereby indirectly inactivating NDM-1. Aspergillomarasmine A causes the loss of Zn2+ ions from the low-affinity binding site of NDM-1. The action of Aspergillomarasmine A results in the rapid degradation of Zn2+-deficient NDM-1, thereby enhancing its potency as a β-lactam enhancer. The mechanism of Aspergillomarasmine A has broad applicability among different Zn2+ chelators [1].
    Aspergillomarasmine A
  • HY-162493
    MBL-IN-3

    		Bacterial Infection
    MBL-IN-3 (compound 72922413) is a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor(IC50=54±4 μM). MBL-IN-3 is identified and shown to lower minimum inhibitory concentrations (MICs) of Meropenem (HY-13678) for a panel of E. coli and K. pneumoniae clinical isolates expressing NDM-1. MBL-IN-3 can be used for antibiotic sensitizer research [1].
    MBL-IN-3
  • HY-N12763
    Sodium new houttuyfonate

    SNH

    		 Bacterial Renin Inflammation/Immunology
    Sodium new houttuyfonate (SNH) is a partially reversible NDM-1 inhibitor with an IC50 of 14.2 μM. Sodium new houttuyfonate is an inhibitor against renin and angiotensin I converting enzyme (ACE). Sodium new houttuyfonate can recover the antibacterial activity of Meropenem (HY-13678) against E. coli BL21/pET15b-blaNDM-1 [1].
    Sodium new houttuyfonate
  • HY-158375
    MBL-IN-4

    		Beta-lactamase Bacterial Infection
    MBL-IN-4 (compound 4b) is a MBL inhibitor with the IC50 of 4.81 and 33 μM against IMP-1 and NDM-1 [1].
    MBL-IN-4
  • HY-153329
    TNF-α-IN-9

    		TNF Receptor Others
    TNF-α-IN-9 (compound 48) is a analog of NDM-1 inhibitor-3 (HY-150758). TNF-α-IN-9 is a TNF-α inhibitor. TNF-α-IN-9 shows low inhibitory activity [1].
    TNF-α-IN-9
  • HY-144259
    Metallo-β-lactamase-IN-2

    		Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-4 (compound 40) is a potent metallo-β-lactamases (MBL) inhibitor, with IC50 values of 0.1 μM (VIM-1), 1.3 μM (NDM-1), and 5.0 μM (IMP-7), respectively [1].
    Metallo-β-lactamase-IN-2
  • HY-144262
    Metallo-β-lactamase-IN-4

    		Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-4 (compound 40) is a potent metallo-β-lactamases (MBL) inhibitor, with IC50 values of 0.5 μM (VIM-1), 2.1 μM (NDM-1), and 3.3 μM (IMP-7), respectively [1].
    Metallo-β-lactamase-IN-4
  • HY-144261
    Metallo-β-lactamase-IN-3

    		Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-3 (compound 35) is a potent metallo-β-lactamases (MBL) inhibitor. Metallo-β-lactamase-IN-3 shows high activity against VIM-1 and NDM-1, with IC50 of 0.6 and 1.0 μM, respectively. Metallo-β-lactamase-IN-3 does not show inhibition of IMP-7 [1].
    Metallo-β-lactamase-IN-3
  • HY-155201
    YJ182

    		Bacterial Infection
    YJ182 is a NDM-1 inhibitor (IC50: 0.23 μM). YJ182 also inhibits IMP-1, VIM-2, GIM-1, and MMP-2, with IC50s of 0.25, 0.61, 0.49, and 6.92 μM respectively. YJ182 can be used for bacterial infection research [1].
    YJ182
  • HY-121765R
    Dacisteine (Standard)

    N,S-Diacetyl-L-cysteine (Standard)

    		 Endogenous Metabolite Metabolic Disease
    Dacisteine (Standard) is the analytical standard of Dacisteine. This product is intended for research and analytical applications. Dacisteine (N,S-Diacetyl-L-cysteine) is a cysteine derivative and displays a less New Delhi metallo-beta-lactamase-1 (NDM-1) inhibitor with an IC50 value of 1000 μM [1]. Dacisteine can be used for the treatment of cardiovascular and cerebrovascular diseases caused by platelet aggregation .
    Dacisteine (Standard)
  • HY-B0368
    Captopril
    Maximum Cited Publications
    16 Publications Verification

    SQ 14225

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease Cancer
    Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM [1] .
    Captopril
  • HY-B0368A
    Captopril hydrochloride

    SQ 14225 hydrochloride

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Captopril (SQ 14225) hydrochloride, antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril hydrochloride is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM [1] .
    Captopril hydrochloride
  • HY-144659
    Metallo-β-lactamase-IN-5

    		Beta-lactamase Apoptosis Bacterial Infection
    Metallo-β-lactamase-IN-5 (compound 5c) is a potent metallo-β-lactamases (MBL) inhibitor. Metallo-β-lactamase-IN-5 shows inhibitory activity against MBLs NDM-1 and VIM-1. Metallo-β-lactamase-IN-5 inhibits HUVECs with an IC50 of 45 μg/mL. Metallo-β-lactamase-IN-5 plus Imipenem exhibits synergistic antimicrobial activity [1].
    Metallo-β-lactamase-IN-5
  • HY-146637
    VIM-2-IN-1

    		Beta-lactamase Bacterial Infection
    VIM-2-IN-1 (compound 1dj) is a β-lactamase inhibitor with antibacterial activities. VIM-2-IN-1 has moderate IC50 values of 23 µM, 48 µM and 231 µM for Verona integron-encoded metallo-β-lactamase (VIM-2), German imipenemase-1 (GIM-1) and New Delhi metallo-β-lactamase (NDM-1), respectively [1].
    VIM-2-IN-1
  • HY-161094
    Metallo-β-lactamase-IN-12

    		Beta-lactamase Bacterial Infection
    Metallo-β-lactamase-IN-12 is a dual inhibitor of metal β-lactamases (MβLs (NDM-1, IMP-1)) and serine β-lactamases (SβLs (OXA-48, KPC-2)), with IC50 values of 0.64 μM, 1.32 μM, 1.01 μM, and 0.57 μM, respectively. Metallo-β-lactamase-IN-12 has antibacterial activity [1].
    Metallo-β-lactamase-IN-12
  • HY-162174
    MBL-IN-2

    		Beta-lactamase Bacterial Infection
    MBL-IN-2 ((2R, 2R')-5αC) is an inhibitor of Metallo-β-lactamase (MBL) that can inhibit New Delhi Metallo-β-lactamase-1 (NDM-1) with an IC50 of 0.3 μM. MBL-IN-2 ((2R, 2R')-5αC) can be used for the study of resistance to β-lactam antibiotics [1].
    MBL-IN-2
  • HY-B0368S
    Captopril-d3

    SQ 14225-d3

    		 Isotope-Labeled Compounds Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Captopril-d3 is deuterium labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM[1][2][3].
    Captopril-d3
  • HY-B0368R
    Captopril (Standard)

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease Cancer
    Captopril (Standard) is the analytical standard of Captopril. This product is intended for research and analytical applications. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM [1] .
    Captopril (Standard)
  • HY-161310
    Metallo-β-lactamase-IN-15

    		Beta-lactamase Infection
    Metallo-β-lactamase-IN-15 (Compound ±13) is a potent MBL inhibitor, the IC50 values for NDM-1、IMP-1 and VIM-2 were 0.29 μM, 0.088 μM and 0.063 μM, respectively [1].
    Metallo-β-lactamase-IN-15
  • HY-111521
    Meropenem-vaborbactam

    Carbavance

    		 Others Infection
    Meropenem-vaborbactam is an antibiotic against nonfermenting Gram-negative clinical isolates, including Enterobacteriaceae isolates with resistant and carbapenemase genotypes. The susceptibility of Meropenem-vaborbactam (at an inhibitory concentration of 8 μg/ml) and comparators was tested against 14,304 nonfermenting Gram-negative clinical isolates collected worldwide in 2014 by reference broth microdilution. Carbapenemase-encoding genes were screened by PCR and sequencing. At concentrations of ≤1 and ≤2 μg/ml, Meropenem-vaborbactam inhibited 99.1 and 99.3% of the 10,426 Enterobacteriaceae isolates tested, respectively, while Meropenem inhibited 97.3 and 97.7% of these isolates at the same concentrations. For isolates displaying carbapenem-resistant Enterobacteriaceae (CRE) (n = 265), multiagent-resistant (MDR) (n = 1,210), and extensively agent-resistant (XDR) (n = 161) phenotypes, meropenem-vaborbactam had MIC50/90 values of 0.5/32, 0.03/1, and 0.5/32 μg/ml, respectively, while meropenem activity was 16/>32, 0.06/32, and 0.5/32 μg/ml, respectively. Among all geographic regions, activity was highest in the United States against CRE and MDR isolates (MIC50/90, 0.03/1 and 0.03/0.12 μg/ml, respectively). Meropenem-vaborbactam was highly active against 135 KPC-producing isolates, with all isolates inhibited at concentrations ≤8 μg/ml (133 isolates were inhibited at concentrations ≤2 μg/ml). The combination had limited activity against isolates producing metallo-β-lactamases (including 25 NDM-1 and 16 VIM producers) and/or oxocephalosporinases (27 OXA-48/OXA-163 producers), which were mainly found in the Asia-Pacific region and some European countries. Meropenem-vaborbactam had activity comparable to meropenem against Pseudomonas spp., Acinetobacter spp., and Clostridium amylovora. Meropenem-vaborbactam was active against a global collection of contemporary Enterobacteriaceae isolates, and the combination had greater activity against CRE isolates and KPC producers than did meropenem and most comparators, which are often multiagent-resistant.
    Meropenem-vaborbactam

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: